Adagene Reports Financial Results for the Six Months Ended June 30, 2022 and Provides Corporate Updates
30 août 2022 17h25 HE
|
Adagene Inc.
– Topline data for anti-CTLA-4 antibody, ADG116, shows compelling clinical safety and complete and partial responses as both a single agent and in combination with anti-PD-1 therapy; results to be...
Adagene Announces Authorization of Share Repurchase Program up to US$10 Million
29 juin 2022 16h05 HE
|
Adagene Inc.
SAN DIEGO and SUZHOU, China, June 29, 2022 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a company transforming the discovery and development of novel antibody-based therapies, today...
Adagene Announces Publication at ASCO of Interim Monotherapy Dose Escalation Data Showing Compelling Safety Profile of Anti-CTLA-4 SAFEbody® ADG126, with Repeat Dosing Across Dose Levels
26 mai 2022 17h00 HE
|
Adagene Inc.
- First clinical data demonstrating potential of SAFEbody technology platform to create best-in-class therapeutics - - Additional data from ongoing ADG126 clinical program to be...
Adagene to Participate in Investor Conferences in May and June
12 mai 2022 07h00 HE
|
Adagene Inc.
SAN DIEGO and SUZHOU, China, May 12, 2022 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a company transforming the discovery and development of novel antibody-based therapies, today...
Adagene Presents Data Demonstrating First and Best-in-Class Potential for Differentiated Preclinical Antibody Candidates at American Association for Cancer Research (AACR) Annual Meeting 2022
08 avr. 2022 13h09 HE
|
Adagene Inc.
- Poster presentations showcase SAFEbody® precision masking technology applicability across targets and modalities – - IND or equivalent filings planned for two new product candidates in 2022,...
Adagene Reports Full Year 2021 Financial Results and Provides Corporate Update
31 mars 2022 08h30 HE
|
Adagene Inc.
- 2022 clinical data readouts on track to show potential best-in-class safety profile for anti-CTLA-4 programs (ADG116, ADG126) with PD-1 for proven and new indications, thereby enabling greater...
天演宣布出席第十九届摩根士丹利全球医疗健康年会
02 sept. 2021 07h45 HE
|
Adagene Inc.
中国苏州和美国旧金山, Sept. 02, 2021 (GLOBE NEWSWIRE) -- 天演药业（以下简称“公司”或“天演”）（纳斯达克股票代码：ADAG）是一家平台驱动的临床阶段生物制药公司，致力于发现并开发以原创抗体为基石的新型癌症免疫疗法。公司今日宣布，天演联合创始人、首席执行官兼董事长罗培志博士将参加2021年9月9日至15日线上举行的第十九届摩根士丹利全球医疗健康年会。 ...
Adagene to Participate at the Morgan Stanley 19th Annual Global Healthcare Conference
02 sept. 2021 07h45 HE
|
Adagene Inc.
SAN FRANCISCO, Calif. and SUZHOU, China, Sept. 02, 2021 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a platform-driven, clinical-stage biopharmaceutical company committed to...
Adagene Reports Financial Results for the Six Months Ended June 30, 2021 and Provides Corporate Updates
26 août 2021 07h45 HE
|
Adagene Inc.
- Established three clinical collaborations with Merck to conduct global combination trials with pembrolizumab for three clinical-stage oncology candidates - - Evidence of ADG106 efficacy with...
Adagene Announces the Third Clinical Trial Collaboration with Merck to Advance Anti-CD137 Agonist, ADG106, in Combination Therapy with KEYTRUDA® (pembrolizumab)
19 août 2021 07h00 HE
|
Adagene Inc.
SAN FRANCISCO, Aug. 19, 2021 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a platform-driven, clinical-stage biopharmaceutical company committed to transforming the discovery and...